The 4 linked references in paper N. Pogudina L., E. Kosolapov G., F. Kochenkov S., A. Karaulov V., N. Bondarenko L., D. Blinov V., Н. Погудина Л., Е. Косолапов Г., Ф. Коченков С., А. Караулов В., Н. Бондаренко Л., Д. Блинов В. (2017) “Сравнительный анализ минимизации затрат и влияния на бюджет фиксированных комбинаций ингаляционных глюкокортикостероидов и длительно действующих бета-агонистов для лечения астмы // COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA” / spz:neicon:pharmacoeconomics:y:2017:i:2:p:12-21

  1. Svedsater H., Stynes G., Wex J. et al. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthmamixed treatment comparisons of clinical efficacy. Asthma Res Pract. 2016; 8 (2): 4. DOI: 10.1186/s40733-015-0016-0.
  2. European Medicines Agency. Summary of product characteristics: Relvar Ellipta inhalation powder. 2013. URL: http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/002673/WC500157633.pdf. Accessed: 22.12.2016.
  3. Hren R., Stynes G. Cost-Minimization and Budget-Impact Analysis of Fixed-Dose Combination Inhalers in Treatment of COPD in Slovenia. Value Health. 2014; 17 (7): A592. DOI: 10.1016/j. jval.2014.08.2032.
  4. Hren R., Trkman M., Stynes G. Cost-Minimization and BudgetImpact Analysis of Fixed-Dose ICS/LABA Combination Inhalers in the Treatment of Asthma in Slovenia. Value Health. 2014; 17 (7): A592. DOI: 10.1016/j.jval.2014.08.2031.